Eterna Therapeutics acquires Exacis Biotherapeutics' IP assets in stock-and-contingent deal

Ernexa Therapeutics Inc.

Eterna issued 69,343 shares to Exacis at closing; shares subject to 12-month lockup.
Contingent milestone: if market cap hits $100M, additional $2M in shares; at $200M, another $2M in shares.
Eterna to pay Exacis 20% of sublicensing revenue received within 5 years, capped at $45M.
CEO Matthew Angel is co-founder of Factor Bioscience (Exacis parent); director Gregory Fiore is CEO of Exacis; deal approved by audit committee and disinterested directors.
Eterna assumes only post-closing liabilities under the purchased license; Exacis retains other liabilities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.